Core Insights - The company is navigating a challenging capital markets environment while completing significant development and regulatory work [3] - The approval of VMS version 4 provides a stronger foundation for commercialization and a clear path for scaling commercial adoption [3] - The strategic focus is shifting from product development to commercial adoption and market expansion, particularly in congenital heart defect centers [5] Business Strategy - The business plan has been reviewed and updated, optimizing marketing processes and expanding the commercial footprint [4] - There is tangible progress in structuring the sales process and strengthening partnerships in preparation for growth [4] - The company aims to transition VMS from research settings to routine clinical use [5]